Top Markets
#1 Palladium Network Palladium Network +27.92%
#2 Siren Siren +25.01%
#3 Ankr Network Ankr Network +20.98%
#4 BankrCoin BankrCoin +19.15%
#5 Status Status +12.14%
#6 Hive Hive +11.15%
#7 Pons Pons +9.35%
#8 Provenance Blockchain Provenance Blockchain +9.13%
#9 Prom Prom +8.82%
#10 Useless Coin Useless Coin +8.39%
Coin of the day
Palladium Network Palladium Network
Settings
Language
ENGLISH
Currency
USD
Theme
Apollo Endosurgery, Inc. Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc.

APEN
Rank in Stocks #18060
Apollo Endosurgery, Inc. is a medical technology firm specializing in the... Apollo Endosurgery, Inc. is a medical technology firm specializing in the creation, development, and commercialization of advanced medical instruments. Among its products are the OverStitch and OverStitch Sx Endoscopic Suturing Systems, which empower physicians to perform advanced endoscopic procedures by suturing and securing tissue approximation via a flexible endoscope. The company also features the Orbera intragastric balloon system, available under brands such as Orbera Intragastric Balloon System, BIB, and Orbera365 Managed Weight Loss System. This system aids in weight management by decreasing stomach capacity and slowing gastric emptying, thereby encouraging reduced food intake. Additionally, it provides the X-Tack Endoscopic HeliX Tacking System, a suture-based device designed for repairing defects in both the upper and lower gastrointestinal tract. Its medical solutions are distributed to various healthcare providers, including hospitals, outpatient surgical centers, clinics, and individual physicians, across the United States, Australia, Costa Rica, and several European nations. Founded in 2005, Apollo Endosurgery, Inc. maintains its headquarters in Austin, Texas.
Share Price
$10.00
Last synced: 2023-04-11
Market Cap
$214.01M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Apollo Endosurgery, Inc. (APEN)

Category

Healthcare
P/E ratio for Apollo Endosurgery, Inc. (APEN)
P/E ratio as of 2026 TTM: 0
According to Apollo Endosurgery, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Apollo Endosurgery, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.48 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 33.28 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 19.48 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.16 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.